Filippo Crea
doi : 10.1093/eurheartj/ehac621
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4443–4446
Benoit J Arsenault
doi : 10.1093/eurheartj/ehac394
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4447–4449
Metin Avkiran
doi : 10.1093/eurheartj/ehac510
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4450–4452
Alberto Giannoni, Francesco Gentile, Claudio Passino
doi : 10.1093/eurheartj/ehac343
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4453–4455
Rocco Vergallo, Carlo Patrono
doi : 10.1093/eurheartj/ehac503
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4456–4457
Franck Thuny, Jarushka Naidoo, Tomas G Neilan
doi : 10.1093/eurheartj/ehac456
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4458–4468,
Over the last decade or so, there has been a paradigm shift in the oncologic care of patients with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic chemotherapy and towards personalized cancer treatments, using both targeted therapy and immunotherapy.
Toru Kondo, Azmil H Abdul-Rahim, Atefeh Talebi, William T Abraham, Akshay S Desai, Kenneth Dickstein, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Milton Packer, Mark Petrie, Piotr Ponikowski, Jean L Rouleau, Marc S Sabatine, Karl Swedberg, Michael R Zile, Scott D Solomon, Pardeep S Jhund, John J V McMurray
doi : 10.1093/eurheartj/ehac487
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4469–4479
Patients with heart failure with reduced ejection fraction (HFrEF) are at significant risk of stroke. Anticoagulation reduces this risk in patients with and without atrial fibrillation (AF), but the risk-to-benefit balance in the latter group, overall, is not favourable.
Dimitrios Sagris, Eduard Shantsila, Gregory Y H Lip
doi : 10.1093/eurheartj/ehac493
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4480–4482
Liesbet Van Bulck, Eva Goossens, Lucas Morin, Koen Luyckx, Fouke Ombelet, Ruben Willems, Werner Budts, Katya De Groote, Julie De Backer, Lieven Annemans, Stéphane Moniotte, Michèle de Hosson, Arianne Marelli, Philip Moons, BELCODAC consortium
doi : 10.1093/eurheartj/ehac484
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4483–4492
Although life expectancy in adults with congenital heart diseases (CHD) has increased dramatically over the past five decades, still a substantial number of patients dies prematurely.
Jill M Steiner, James N Kirkpatrick
doi : 10.1093/eurheartj/ehac492
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4493–4495
Dongchao Lu, Shambhabi Chatterjee, Ke Xiao, Isabelle Riedel, Cheng-Kai Huang, Alessia Costa, Sarah Cushman, Dimyana Neufeldt, Laura Rode, Arne Schmidt, Malte Juchem, Julia Leonardy, Gwen Büchler, Jonas Blume, Olivia-Luise Gern, Ulrich Kalinke, Wilson Lek Wen Tan, Roger Foo, Aryan Vink, Linda W van Laake, Peter van der Meer, Christian Bär, Thomas Thum
doi : 10.1093/eurheartj/ehac337
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4496–4511
Cardiotoxicity leading to heart failure (HF) is a growing problem in many cancer survivors. As specific treatment strategies are not available, RNA discovery pipelines were employed and a new and powerful circular RNA (circRNA)-based therapy was developed for the treatment of doxorubicin-induced HF.
Carlo G Tocchetti, Alessandra Ghigo, Emilio Hirsch
doi : 10.1093/eurheartj/ehac407
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4512–4514
Nicole K Bart, Eugene Kotlyar, Anne M Keogh
doi : 10.1093/eurheartj/ehac499
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Page 4515
Kazunori Omote, Barry A Borlaug
doi : 10.1093/eurheartj/ehac540
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Pages 4516–4517
Jeffrey B Geske, Elizabeth H Stephens, Joseph A Dearani
doi : 10.1093/eurheartj/ehac439
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Page 4518
Juan Caro-Codón, Samuel López Muñoz, Esteban López-de-Sa
doi : 10.1093/eurheartj/ehac507
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Page 4519
doi : 10.1093/eurheartj/ehac458
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Page 4468
doi : 10.1093/eurheartj/ehac529
European Heart Journal, Volume 43, Issue 42, 7 November 2022, Page 4482
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟